Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Ono Pharmaceutical synthesizes bispecific antibodies targeting CD19 and PD-1

Oct. 16, 2020

Ankasa begins phase Ib/IIa evaluation of ART352-L in posterolateral spinal fusion

Oct. 15, 2020

New MAP3K5 inhibitors identified at Enanta Pharmaceuticals

Oct. 15, 2020

Allob shows 90% fusion rate at 24 months in phase IIa study in lumbar spinal fusion

Oct. 14, 2020

SynAct advances phase IIa study of AP-1189 in rheumatoid arthritis

Oct. 13, 2020

Phase II study of mavrilimumab in giant cell arteritis meets efficacy endpoints

Oct. 7, 2020

NMD Pharma begins phase I/IIa trial of NMD-670 to treat symptoms of myasthenia gravis

Oct. 6, 2020

Zhejiang Huahai Pharmaceutical, Shanghai Synergy Pharmaceutical Sciences disclose JAK inhibitors

Oct. 2, 2020

FDA approves Simponi Aria for pJIA and PsA in pediatric patients

Oct. 2, 2020

Optimization of selective TLR7/TLR8 dual antagonists using a new antagonist competition assay

Oct. 2, 2020

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...